An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
There are five approved biosimilars for Eylea - Amgen's Pavblu, Sandoz's Enzeevu, Formycon's Ahzantive, Samsung Bioepis' Opuviz and Biocon Biologics' Yesafili. Alvotech is also developing AVT29 ...
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...